Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annu...( SAN FRANCISCO May 15 /- Medivatio...),Health

SAN FRANCISCO, May 15 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that data from an ongoing Phase 1-2 clinical trial of its novel androgen receptor antagonist, MDV3100, will be presented in an oral presentation at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Session title: New Targeted Strategies for Patients with Prostate Cancer

Session date and time: Monday, June 2 at 11:30 a.m. Central Time

Abstract title: "Phase 1-2 Study of MDV3100 in Patients with Progressive

Castration-Resistant Prostate Cancer (CRPC)" (Abstract #5006)

To be presented by: Howard Scher, M.D., chief of the Genitourinary

Oncology Service and the D. Wayne Calloway Chair in Urologic Oncology at

Memorial Sloan-Kettering Cancer Center in New York, at approximately 12:15

p.m. Central Time

Location: W375e

Dr. Scher's presentation will include data appearing in the abstract posted today on the ASCO website, as well as additional study data not reflected in the abstract.

Medivation's ongoing Phase 1-2 trial of MDV3100 is an open-label dose-escalation study enrolling prostate cancer patients who have failed standard hormonal therapies. The study endpoints include safety, tolerability, pharmacokinetics, effects on serum PSA levels and disease progression. Medivation expects to complete the study and report final top-line results in 2008.

About Prostate Cancer

Prostate cancer is the most common type of cancer, other than skin cancer, and the second leading cause of cancer death in American men. More than 1 million men in the United States have prostate cancer. An estimated 186,320 new cases are expected to be diagnosed in 200
'/>"/>